Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Head and Neck

Volumn 22, Issue 3, 2000, Pages 257-264

  Bhatavdekar, Jyotsna M ^a   Patel, Devendra D ^a   Vora, Hemangini H ^a   Shah, Neelam G ^a   Chikhlikar, Priya R ^a   Ghosh, Nandita ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Locally advanced tongue cancer; Prolactin

Indexed keywords

MESSENGER RNA; PROLACTIN; PROLACTIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TONGUE CANCER; TUMOR GROWTH;

ADULT; AGED; ANALYSIS OF VARIANCE; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROLACTIN; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TONGUE NEOPLASMS;

EID: 0033994932     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0347(200005)22:3<257::AID-HED8>3.0.CO;2-K     Document Type: Article

References (42)

1. Bhatavdekar JM, Trivedi SN, Shah NG, et al. Comparison of prolactin, CA 15-3 and TPA in breast carcinoma. Int J Biol Markers 1989;4:150-156.
2. Bhatavdekar JM, Giri DD, Shah NG, et al. Prolactin in advanced breast cancer An Indian experience. Breast Dis 1990;3:199-204.
3. Bhatavdekar JM, Giri DD, Shah NG, et al. Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 1990;65:2028-2032.
4. Bhatavdekar JM, Patel DD, Giri DD, et al. Plasma prolactin and prognosis in advanced breast cancer. Breast Dis 1993;6:107-111.
5. Bhatavdekar JM, Patel DD, Karelia NH, et al. The clinical significance of prolactin, TPS, CA 15-3 and CEA in patients with breast cancer. Breast Dis 1993;6:177-183.
6. Bhatavdekar JM, Patel DD, Sherbet GV, et al. Prognostic significance of plasma prolactin in breast cancer: Comparison with the expression of c erb B-2 oncoprotein. Eur J Surg Oncol 1993;19:409-414.
7. Bhatavdekar JM, Patel DD, Karelia NH, et al. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer? Eur J Surg Oncol 1994;20: 118-121.
8. Bhatavdekar JM, Patel DD, Karelia NH, et al. Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat 1994;30:293-297.
9. Bhatavdekar JM, Patel DD, Vora HH, et al. Comparison of prognostic value of plasma prolactin with that of receptors for prolactin, epidermal growth factor, estrogen and progesterone in patients with stage III breast cancer. Breast Dis 1995;8:319-326.
10. Bhatavdekar JM, Patel DD, Shah NG, et al. Factors influencing prognosis in axillary node-positive breast carcinoma: Analysis of plasma prolactin and insulin-like growth factor-1 receptor. Gujarat Cancer Res Inst Bull 1996;3:46-53.
11. Patel DD, Bhatavdekar JM, Chikhlikar P, et al. Node-negative breast carcinoma: Hyperprolactinemia/overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62:86-92.
12. Bhatavdekar JM, Patel DD, Giri DD, et al. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Br J Cancer 1992; 66:977-980.
13. Patel DD, Bhatavdekar JM, Ghosh N, et al. Plasma prolactin in patients with colorectal cancer: value in follow-up and as a prognosticator. Cancer 1994;73:570-574.
14. Bhatavdekar JM, Patel DD, Vora HH, et al. Prolactin: Its role in locally advanced tongue cancer. J Surg Oncol 1994; 57:115-120.
15. UICC. TNM classification of malignant tumors. UICC Tech Rep Series 1980;5:2.
16. Broders AC. Microscopic grading of cancer. Surg Clin North Am 1941;21:947-962.
17. Patel DD, Bhatavdekar JM, Vora HH, Balar DB. Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study. Eur J Surg Oncol 1994;20:155-159.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
19. Sambrook J, Fritsch EF, Maniatis T. Analysis and cloning of eukaryotic genomic DNA. In: Nolan C, editor. Molecular cloning: A laboratory manual. New York: Cold Spring Harbour Laboratory Press; 1989. p 9.1-9.62.
20. Norusis MJ. In: SPSS for windows : Advanced statistics, release 6.0. Chicago: SPSS Inc; 1993.
21. Molitch ME, Schwartz S, Mukherji B. Is prolactin secreted ectopically? Am J Med 1981;70:803-807.
22. Bhatavdekar JM, Patel DD, Vora HH, Balar DB. Circulating markers and growth factors as prognosticators in men with locally advanced tongue cancer. Tumor Biol 1993;14:55-58.
23. Bhatavdekar JM, Patel DD, Vora HH, Balar DB. Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study. Anticancer Res 1993;13:237-240.
24. Vora HH. Expression of tumor markers in the management of tongue carcinoma. PhD Thesis, Gujarat University, 1994.
25. Peyrat JP, Djiane J, Bonneterre J, et al. Stimulation of DNA synthesis by prolactin in human breast tumor explants: Relation to prolactin receptors. Anticancer Res 1984;4:257-262.
26. Clapp C. Analysis of proteolytic cleavage of prolactin by mammary gland and liver of the rat: characterization of the cleaved and 16K forms. Endocrinology 1987;121: 2055-2064.
27. Bhatavdekar JM, Patel DD, Ghosh N, et al. Interrelationship of prolactin and its receptor in carcinoma of colon and rectum. A preliminary report. J Surg Oncol 1994;55: 246-249.
28. Banerjee R, Ginsburg E, Vonderhaar BK. Characterization of a monoclonal antibody against human prolactin receptors. Int J Cancer 1993;55:712-721.
29. Ormandy CJ, Sutherland RL. Mechanisms of prolactin receptor regulation in mammary gland. Mol Cell Endocrinol 1993;91:C1-C6.
30. Lesueur L, Edery M, Ali S, Paly J, Kelly PA, Djiane J. Comparison of long and short forms of prolactin receptors on prolactin induced milk protein gene transcription. Proc Natl Acad Sci USA 1991;88:824-828.
31. Clevenger CV, Medaglia MV. The protein tyrosine kinase p59tyn is associated with prolactin receptor and is activated by prolactin stimulation of T-lymphocytes. Mol Endocrinol 1994;8:674-681.
32. Clevenger CV, Torigoe T, Reed JC. Prolactin induces rapid phosphorylation and activation of prolactin receptor associated Raf-1 kinase in a T-cell line. J Biol Chem 1994; 269:5559-5565.
33. Rui H, Kirken RA, Farrar WL. Activation of receptor associated tyrosine kinase JAK2 by prolactin. J Biol Chem 1994;269:5364-5368.
34. Ali S, Edery M, Pelligrini I, Paly J, Djiane J, Kelly PA. Functional activity of three different forms of the rat prolactin receptor [abstract], Endocrinol Soc 1991;73:245A.
35. Wander HE, Blossey CH, Kobberling J, Nagel GA. High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of disease and hormone profiles. Klin Wochenschr 1983;61:553-560.
36. Bhatavdekar JM, Vora HH, Goyal A, Shah NG, Karelia NH, Trivedi SN. Significance of ferritin as a marker in head and neck malignancies. Tumori 1987;73:59-64.
37. Bhatavdekar JM, Vora HH, Patel DD. Serum sialic acid forms as markers for head and neck malignancies. Neoplasma 1988;35:425-434.
38. Bhatavdekar JM, Patel DD, Vora HH, Balar DB. Squamous cell carcinoma antigen and protein bound sialic acid in the management of head and neck cancer patients. Int J Biol Markers 1991;6:237-240.
39. Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 1990;15:3-11.
40. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980;303:878-880.
41. Lee NK. Oncogenes. Head Neck 1992;14:235-242.
42. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-1292.